

This invention provides liposomic composition, containing as active ingredient (-)-N- α -dimethyl-N-(2-propylphenylethylamine) (selegilin) and/or salt thereof. This composition contains: 0,1-40 % by weight of selegilin and/or a salt thereof, 2 to 40 % by weight of lipids, preferably phospholipids, 0 to 10 % by weight of cholesterol, 0 to 20 % by weight of an alcohol, 0 to 25 % by weight of a glycol, 0 to 3 % by weight of an antioxidant, 0 to 3 % by weight of a preserving agent, 0 to 2 % by weight of a viscosity influencing agent, 0 to 50 % by weight of cyclodextrin or a cyclodextrin derivative and 30 to 90 % by weight of water. This invention provides the process for the preparation of liposomic compositions containing selegilin and/or salt thereof. Accordingly liposomic composition of this invention may be administered for the treatment of Alzheimer's disease, Parkinson's disease, depression, stroke, motion sickness or myelitis.